BridgeBio Oncology Therapeutics (BBOT) raised $200m in a private financing round led by Cormorant Asset Management and Omega Funds to expedite precision oncology pipeline development.
Amount Raised
$200
Round Type
Pre-Seed
Palo AltoBiotechnologyHealth CareTherapeuticsInvestors
Description
BridgeBio Pharma has announced the launch of BridgeBio Oncology Therapeutics (BBOT), supported by $200m of private external capital to expedite the development of the company’s precision oncology pipeline, focusing on new cancer treatments.
Quick answer
BridgeBio raised $200 in a Pre-Seed round, dated May 3, 2024. Investors: GV, Enavate Sciences, Eco R1 Capital, Wellington Management, Deerfield Management, Omega Funds and Cormorant Asset Management. BridgeBio is based in Palo Alto, California, United States.
- How much did BridgeBio raise?
- BridgeBio raised $200 in a Pre-Seed round on May 3, 2024.
- Who invested in BridgeBio?
- GV, Enavate Sciences, Eco R1 Capital, Wellington Management, Deerfield Management, Omega Funds and Cormorant Asset Management are named as investors in this round.
- What does BridgeBio do?
- BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.
- Where is BridgeBio based and how big is it?
- BridgeBio is based in Palo Alto, California, United States. Fundz records about 730 employees.
- Who are the decision-makers at BridgeBio?
- Fundz holds 1 contact at BridgeBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as BridgeBio that raised within 45 days of this round, from Fundz verified event records.
- InduPro raised $85M (Series A) on June 13, 2024.
- Amber Therapeutics raised $100M (Series A) on June 10, 2024.
- Calidi Biotherapeutics raised $5.5M on June 3, 2024.
- Aptose Biosciences raised $4.4M (Seed) on June 3, 2024.
- Summit Therapeutics raised $200M on June 3, 2024.
- Radiomer Therapeutics raised an undisclosed amount (Pre-Seed) on May 29, 2024.
Who to call at BridgeBio, and when
A new round usually means BridgeBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BridgeBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BridgeBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BridgeBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
BridgeBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.